Rhabdomyosarcoma xenotransplants in zebrafish embryos

Abstract: Rhabdomyosarcomas (RMS) are the most common pediatric soft tissue sarcomas. High-risk and metastatic disease continues to be associated with very poor prognosis. RMS model systems that faithfully recapitulate the human disease and provide rapid, cost-efficient estimates of antitumor efficacy of candidate drugs are needed to facilitate drug development and personalized medicine approaches. Here, we present a new zebrafish-based xenotransplant model allowing for rapid and easily accessible drug screening using low numbers of viable tumor cells and relatively small amounts of water-soluble chemicals. Under optimized temperature conditions, embryonal RMS xenografts were established in zebrafish embryos at 3 h postfertilization (hpf). In proof-of-principle experiments, chemotherapy drugs with established clinical anti-RMS efficacy (vincristine, dactinomycin) and the mitogen-activated protein kinase kinase inhibitor trametinib were shown to significantly reduce the cross-sectional area of the tumors by 120 hpf. RMS xenograft models in zebrafish embryos henceforth could serve as a valuable addition to cell culture and mammalian models of RMS and represent a rapid and cost-effective solution for preclinical candidate drug testing

Objekt anzeigen

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch
• Anmerkungen: Pediatric blood & cancer. - 70, 1 (2023) , e30053, ISSN: 1545-5017

Beteiligte, Orts- und Zeitangaben

• Ereignis: Veröffentlichung
• (wo): Freiburg
• (wer): Universität
• (wann): 2022
• Urheber: Siebert, Jakob ; Schneider, Michaela ; Reuter‐Schmitt, Daniela ; Würtemberger, Julia ; Neubüser, Annette ; Driever, Wolfgang ; Hettmer, Simone ; Kapp, Friedrich

Weitere Informationen

• DOI: 10.1002/pbc.30053
• URN: urn:nbn:de:bsz:25-freidok-2311211
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.